论文部分内容阅读
目的:研究思密达联合双岐杆菌三联活菌散治疗小儿病毒性肠炎的临床疗效;方法:选取我院近年收治的小儿病毒性肠炎108例进行临床研究,对照组54例口服思密达,研究组54例口服思密达和双岐杆菌三联活菌散(培菲康),比较2组疗效。结果:研究组显效率51.9%、总有效率92.6%明显高于对照组的21.4%、74.1%(p<0.05),无效率7.4%显著低于对照组的25.9%(p<0.01)。结论:双歧三联活菌散剂联合思密达治疗小儿病毒性肠炎的临床效果确切,安全性较好。
Objective: To study the clinical efficacy of Smecta combined with Bifidobacterium triple inactivated bacilli in the treatment of viral enteritis in children. Methods: A total of 108 children with viral enteritis treated in our hospital were selected for clinical study. The control group, The study group of 54 cases of oral smecta and Bifidobacterium triple live bacteria powder (Peifenkang), the two groups were compared. Results: The effective rate of the study group was 51.9%, the total effective rate was 92.6%, significantly higher than that of the control group (21.4%, 74.1%, p <0.05), and the inefficiency rate of 7.4% was significantly lower than that of the control group (25.9%, p <0.01). Conclusion: Bifid triple live bacillus powder combined with Smectite treatment of viral enteritis in children is clinically effective and safe.